Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multinational, Multicenter, Clinical Trial of the Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) in Cross-Reacting Immunologic Material-Positive Patients With Classical Infantile Pompe Disease

NCT00025896 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00025896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00025896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multinational, Multicenter, Clinical Trial of the Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) in Cross-Reacting Immunologic Material-Positive Patients With Classical Infantile Pompe Disease
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2001
Completion date
September 30, 2002
Enrollment
8
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acid maltase deficiency disease, glycogen storage disease type ii, glycogenosis 2, pompe disease